Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials

Eitemau Tebyg

• Adjuvant EGFR-TKI therapy in resected EGFR-mutation positive non-small cell lung cancer: A real-world study
  gan: Jun-Feng Liu, et al.
  Cyhoeddwyd: (2023-03-01)
• Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
  gan: Zhang SS, et al.
  Cyhoeddwyd: (2022-04-01)
• The Role of Adjuvant Chemotherapy before Osimertinib in Epidermal Growth Factor Receptor Mutant Resected Non-Small Cell Lung Cancer and Communicating It to Patients
  gan: Paolo Maione, et al.
  Cyhoeddwyd: (2024-02-01)
• Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis
  gan: Jie Wang, MD, PhD, et al.
  Cyhoeddwyd: (2024-02-01)
• Adjuvant EGFR-TKIs for Patients With Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis of 1,283 Patients
  gan: Rui-Lian Chen, et al.
  Cyhoeddwyd: (2021-04-01)